Study Group: Ventavis Prescribers (US)(?)
Council Members in this Study Group: 30
Request a survey with this Study Group
Leading Experts in this Study Group
Ass. Professor in Medicine
University of North Carolina at Chapel Hill School of Medicine - CC
Ray Coakley, MD PhD, is a physician scientist / pulmonary & critical care specialist at the University of North Carolina, Chapel Hill. His clinical and research focus is on COPD, cystic fibrosis, lung transplantation and PAH. Specific research expertise includes airway epithelial ion/fluid transport...
Rheumatologist
HEALTHCARE PARTNERS MEDICAL GROUP
Dipti Doshi, MD, is a board certified Rheumatologist at Health Care Partners Medical group, California. Dr. Doshi is also board certified in Internal Medicine. Her special interests are in rheumatoid arthritis, lupus, pain-related to scleroderma, fibromyalgia, and osteoarthritis. Dr. Doshi is interested...
Robyn Barst, MDFormerDirector
New York- Presbyterian/Columbia University Medical Center
Robyn J Barst, MD is Professor Emeritus of Pediatrics (in Medicine) at the College of Physicians and Surgeons at Columbia University. She was Director of the New York-Presbyterian Pulmonary Hypertension Center 1982-2008. She is a Fellow of the American Academy of Pediatrics, American College of Cardiology,...
Victor Tapson, MDMedical Director of Pulmonary Hypertension Center
Duke University
Victor Tapson, MD, is Professor of Medicine in the Division of Pulmonary and Critical Care at Duke University School of Medicine and the Medical Director of the Duke Pulmonary Hypertension Center. Dr. Tapson was Director for the Duke Lung Transplant Program for over 10 years and Director for the Center...
Assistant Professor & Director
University of Florida
Kamal Mubarak, MD, is an Assistant Professor and Director of the Pulmonary Vascular Disease Program at University of Florida, Gainesville. Dr. Mubarak's clinical specialties include Internal Medicine, Critical Care Medicine, and Pulmonary Disease. He is involved in numerous clinical trials in treating...
Related Study Groups
GLG NewsSMAnalyses by this Study Group's Leading Experts(?)
Drug therapies for RA include (NSAIDS), DMARDS, and, most recently, biologics. Biologics currently on the market for RA target immune messengers called cytokines, which promote the damaging inflammatory process, and include anti-tumor necrosis factor (TNF) drugs – infliximab , etanercept,adalimumab,...
Pharmacokinetic studies of Adlea showed that when it is locally administered to the site of pain, there appears to be limited systemic exposure. Its short duration of systemic exposure (hours) relative to the long duration of analgesia (12 weeks) resulting from a single treatment course of Adlea is...
Very important new treatment emerging in field of rheumatoid arthritis along with other drugs in pipeline. IL-6 receptor blocker. New Mechanism of action. Has positive priliminary endpoint results at 24 week study for RA compared to DMARD therapy alone.
Very nice article. Although sample size seemed very less, avaialble results look very promising. Particularly in contrast of Leevy study. Only concern is of side-effects. Would make things clear on further study with the same drug
United Therapeutics has had the benefit of the doubt re use of IV remodulin based on "relative convenience", despite expense and has not uniformly been adopted across PH centers and providers. Despite the small overall number of infections, the rate of the more life threatening gram negative...
Most Common Company Types:
- Academic Medical Center/Hospital or Clinic
- Non-Academic Community Hospital or Clinic
- Office Based Private Practice or Clinic
- Academic Institution*
- Facility, Academic Medical Center
Most Common Job Types:
- Physician - Attending Physician
- Physician - Director
- Physician - Division Head
- Research Associate
- Operations Executive
- Physician - Fellow
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms